Polyrizon's Intranasal Barrier Technology Shows Promise Against Respiratory Viruses and Allergens
Key Insights
Polyrizon's PL-16 Viral Blocker (search) demonstrated strong protection against H1N1 influenza (search) through a reversible physical barrier mechanism that traps viral particles without cytotoxicity.
The company's PL-14 Allergy Blocker (search) achieved over 60% targeted deposition in the nasal vestibule, the critical entry point for airborne allergens.
Both products utilize Polyrizon's proprietary Capture & Contain hydrogel platform, which forms a protective shield in the nasal cavity without pharmacological intervention.
Polyrizon Ltd. (search) (Nasdaq: PLRZ) has announced positive preclinical results for two intranasal barrier products that demonstrate broad-spectrum protection against respiratory viruses and allergens through a novel physical blocking mechanism. The biotechnology company's proprietary Capture & Contain (C&C) platform showed promising efficacy in separate studies evaluating viral protection and allergen blocking capabilities.
Viral Protection Through Physical Barrier Mechanism
In-vitro studies of Polyrizon's PL-16 Viral Blocker (search) confirmed strong protective effects against H1N1 influenza (search) virus using cell models. Pre-treatment with the nasal gel formulation effectively prevented viral-induced cytopathic effects and maintained high cell viability following viral exposure. The formulation exhibited consistent and robust protection without evidence of cytotoxicity, confirming both safety and efficacy.
A key finding emerged from complementary experiments designed to understand the underlying mechanism of antiviral protection. When virus particles pre-exposed to the formulation were subsequently separated from it prior to cell infection, the viruses regained their full infectivity and induced normal cytopathic effects in host cells. This outcome demonstrates that the formulation does not inactivate or "kill" viruses through pharmacological mechanisms, but rather functions as a temporary, physical barrier preventing viral particles from reaching and entering host cells.
"Demonstrating both strong viral blocking and reversibility is key to establishing the unique nature of our platform," said Tomer Izraeli, Chief Executive Officer of Polyrizon. "These results confirm that our formulation acts as a safe and effective physical barrier, not as a pharmacological agent, and they reinforce our commitment to advancing safe, innovative solutions for respiratory protection."
Targeted Allergen Blocking in Nasal Vestibule
Polyrizon's PL-14 Allergy Blocker (search) showed encouraging preclinical results in a study conducted in collaboration with the University of Parma, Italy. The evaluation, led by Professor Fabio Sonvico from the Department of Food and Drug, used a validated silicone-based human nasal cast and fluorescein-labeled imaging to assess spray deposition profiles under clinically relevant conditions.
The results revealed that PL-14 achieved over 60% deposition in the nasal vestibule, the first physiological region exposed to airborne allergens. This targeted delivery is critical for effectively blocking allergen contact with the nasal mucosa, supporting PL-14's mechanism of action as a physical barrier product designed to capture and contain environmental allergens before they trigger immune responses.
"We believe that the ability of our C&C platform to deliver a high concentration of hydrogel barrier to the vestibular region of the nose is a significant step forward," said Izraeli. "These results support the core principle behind our blocker products—to form a protective layer at the point of allergen entry and prevent the initiation of allergic reactions."
Market Context and Development Path
According to Business Research Insights, the global allergen blocker market was valued at USD 0.14 billion in 2024 and is expected to reach USD 0.21 billion by 2033, exhibiting a compound annual growth rate of 4.4%. The market expansion is driven by rising allergy incidence, greater public awareness of allergens and their health impacts, and increasing demand for allergy relief products.
PL-14's performance in the nasal cast model highlights its potential as a frontline preventive treatment for allergic rhinitis (search). The hydrogel formulation maintained favorable sprayability and coverage under standard administration angles, demonstrating practicality for self-administration.
Technology Platform and Future Development
Polyrizon's C&C hydrogel technology comprises naturally occurring building blocks delivered as nasal sprays that potentially function as a "biological mask" with a thin shield containment barrier in the nasal cavity. The company is also developing aspects of the technology focused on bioadhesion and prolonged retention at nasal deposition sites for intranasal drug delivery, referred to as the Trap and Target (T&T) platform.
Both PL-16 and PL-14 demonstrated the absence of cytotoxicity, and the reversibility of the blocking effects reinforces their safety profiles. Future development will include clinical studies subject to applicable regulatory approvals as Polyrizon continues preclinical validation and advances toward clinical trials for the C&C platform.